menu
    • menu
    [{"orgOrder":0,"company":"Onchilles Pharma","sponsor":"University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"ELANE pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Onchilles Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onchilles Pharma \/ University of Chicago","highestDevelopmentStatusID":"4","companyTruncated":"Onchilles Pharma \/ University of Chicago"},{"orgOrder":0,"company":"Onchilles Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"N17350","moa":"ELANE pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Onchilles Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onchilles Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onchilles Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Onchilles Pharma

    Menu

    Onchilles Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Onchilles Pharma

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Onchilles Pharma

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N17350

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Onchilles Pharma Nominates First Drug Development Candidate Leveraging Neutrophil Biology for the Treatment of...

                            Details : N17350, a first-in-class biologic therapeutic that is designed to leverage the immunobiology of neutrophils, a key part in the innate immune system, against a wide range of cancer types. The company is targeting to start first-in-human clinical trials in...

                            Product Name : N17350

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            December 12, 2022

                            Lead Product(s) : N17350

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Onchilles Pharma

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Onchilles Pharma

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : University of Chicago

                            Deal Size : $7.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Onchilles Pharma Raises $7 Million Series A

                            Details : The proceeds of the financing will be used to develop first-in-class therapeutics to activate a novel pathway of the innate immune system with potential for universal anti-cancer activity, independent of genetic mutation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 06, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : University of Chicago

                            Deal Size : $7.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth